Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer’s Disease

Manuscript Number: 

21-5553R1

Author(s): 
Gary R. Cutter, Byron C. Jaeger, Richard E. Kennedy, Charles Murchison, Erik D. Roberson, Jeff M. Szychowski

Disclosures

Gary R. Cutter

  • Consulting Fees:
    Data and Safety Monitoring Boards: AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, Immunic, Mapi Pharmaceuticals LTD, Merck, Merck/Pfizer, Mitsubishi Tanabe Pharma Holdings, Opko Biologics,Prothena Biosciences, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, NHLBI (Protocol Review Committee), University of Texas Southwestern, University of Pennsylvania, Visioneering Technologies, Inc. Consulting or Advisory Boards: Alexion, Antisense Therapeutics, Biogen, Clinical Trial Solutions LLC, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Merck/Serono, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Protalix Biotherapeutics, Recursion/Cerexis Pharmaceuticals, Regeneron, Roche, SAB Biotherapeutics.
    Equity:
    Dr. Cutter is employed by the University of Alabama at Birmingham and President of Pythagoras, Inc. a private consulting company located in Birmingham AL.

Byron C. Jaeger

  • Nothing to Disclose

Richard E. Kennedy

  • Nothing to Disclose

Charles Murchison

  • Nothing to Disclose

Erik D. Roberson

  • Consulting Fees:
    GLG, Guidepoint
    Patents/Royalties
    Royalties from Genentech for licensing mouse model

Jeff M. Szychowski

  • Nothing to Disclose